Industries > Pharma > Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other

PUBLISHED: 29 June 2017
PAGES: 172
PRODUCT CODE: PHA0207
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0207 Categories: ,

The Non-Small Cell Lung Cancer (NSCLC) Drugs market is estimated at $7.86bn in 2016 and is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.2% during the full forecast period. In 2016, the chemotherapy segment generated a revenue of $3.28bn and represented 41.7% of the total NSCLC drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 172-page report you will receive 133 charts – all unavailable elsewhere.

The 172-page report provides clear detailed insight into the Non-Small Cell Lung Cancer (NSCLC) Drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Non-Small Cell Lung Cancer (NSCLC) Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the main therapeutic segments:
• Chemotherapy
• EGFR and ALK Inhibitors
• VEGF / VEGFR Inhibitors
• Immunotherapy

Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

• This report provides revenue forecast to 2027 for the leading drugs in this market:
Alimta (pemetrexed) by Eli Lilly
Avastin (bevacizumab) by Roche
Tarceva (erlotinib) by Roche
Iressa (gefitinib) by AstraZeneca
Gilotrif (afatinib) by Boehringer Ingelheim
Xalkori (crizotinib) by Pfizer
Abraxane (paclitaxel Protein-Bound) by Celgene
Taxotere (docetaxel) by Sanofi
Cyramza (ramucirumab) by Eli Lilly
Zykadia (ceritinib) by Novartis
Opdivo (nivolumab) by Bristol-Myers Squibb

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• The US
• Japan
• Germany
• France
• Italy
• Spain
• The UK
• China
• Brazil
• Russia
• India
• Rest of the World

• This report also includes a chapter on R&D which discusses some of the most promising and prominent late-stage candidates

• Our study includes a SWOT analysis of this industry and market

• Our study explores the issues and forces that influence the NSCLC drugs market:
• Genetic mutations allowing for targeted therapies, newer medicines offering improved treatment outcomes
• Treatment protocols by stage and for patient populations – maintenance, second-line and third-line therapies
• Regulators’ views and cost-effectiveness – challenges and opportunities in drug approvals, pricing, reimbursement and healthcare budgets
• Recent approval for the NSCLC indication – expanding treatment options
• Overcoming patent expiries and competition from generic drugs
• Identification of biomarkers for targeted therapies, advancing treatment protocols.

Visiongain’s study is intended for anyone requiring commercial analyses for the Non-Small Cell Lung Cancer (NSCLC) Drugs market. You find data, trends and predictions.

Buy our report today Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

    Download sample pages

    Complete the form below to download your free sample pages for Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

      Latest Pharma news

      Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

      The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

      12 April 2024

      READ

      Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

      The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

      11 April 2024

      READ

      Visiongain Publishes Female Health Tech Market Report 2024-2034

      The global Female Health Tech market was estimated to be valued at US$ 140.9 billion in 2034 and is expected to register a CAGR of 9.6% from 2024 to 2034.

      05 April 2024

      READ

      Visiongain Publishes Meningococcal Vaccines Market Report 2024-2034

      The global Meningococcal Vaccines market is projected to grow at a CAGR of 2.5% by 2034

      26 March 2024

      READ